Abbott Laboratories $ABT is Jensen Investment Management Inc.’s 10th Largest Position

Jensen Investment Management Inc. lifted its holdings in Abbott Laboratories (NYSE:ABT) by 1.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,409,429 shares of the healthcare product maker’s stock after acquiring an additional 30,866 shares during the quarter. Abbott Laboratories accounts for 4.0% of Jensen Investment Management Inc.’s holdings, making the stock its 10th biggest position. Jensen Investment Management Inc.’s holdings in Abbott Laboratories were worth $322,719,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the business. IMG Wealth Management Inc. boosted its stake in shares of Abbott Laboratories by 759.1% in the second quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock worth $26,000 after buying an additional 167 shares during the last quarter. Cloud Capital Management LLC acquired a new position in Abbott Laboratories in the third quarter valued at approximately $29,000. Guerra Advisors Inc purchased a new stake in Abbott Laboratories in the 3rd quarter worth approximately $31,000. Anfield Capital Management LLC grew its stake in shares of Abbott Laboratories by 81.3% during the 2nd quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock worth $32,000 after purchasing an additional 104 shares during the period. Finally, Delos Wealth Advisors LLC purchased a new position in shares of Abbott Laboratories during the 2nd quarter valued at approximately $32,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently commented on ABT shares. Leerink Partners dropped their price target on shares of Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating on the stock in a research report on Friday, January 30th. Evercore lowered their target price on shares of Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Mizuho lifted their price target on Abbott Laboratories from $135.00 to $140.00 and gave the company a “neutral” rating in a research note on Tuesday, October 14th. Oppenheimer lowered their price target on Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Finally, Freedom Capital raised Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 29th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $137.05.

Abbott Laboratories Stock Performance

Shares of Abbott Laboratories stock opened at $112.23 on Wednesday. The business’s 50 day moving average price is $120.24 and its 200 day moving average price is $126.70. The company has a market cap of $195.15 billion, a price-to-earnings ratio of 30.17, a PEG ratio of 1.77 and a beta of 0.75. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.24 and a current ratio of 1.70. Abbott Laboratories has a one year low of $105.27 and a one year high of $141.23.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.50. Abbott Laboratories had a return on equity of 17.94% and a net margin of 14.72%.The business had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. During the same period last year, the company earned $1.34 EPS. The company’s revenue for the quarter was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, research analysts predict that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, February 13th. Stockholders of record on Thursday, January 15th will be paid a $0.63 dividend. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.59. The ex-dividend date of this dividend is Thursday, January 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.2%. Abbott Laboratories’s dividend payout ratio is currently 67.74%.

Insider Activity

In other news, Director Daniel J. Starks purchased 10,000 shares of Abbott Laboratories stock in a transaction dated Wednesday, February 4th. The shares were purchased at an average price of $108.73 per share, with a total value of $1,087,300.00. Following the transaction, the director owned 6,738,817 shares in the company, valued at $732,711,572.41. This represents a 0.15% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.46% of the stock is owned by corporate insiders.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.